Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches,Chemical Biology & Drug Design

当前位置： X-MOL 学术 › Chem. Bio. Drug Des. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches
Chemical Biology & Drug Design ( IF 3.2 ) Pub Date : 2021-08-15 , DOI: 10.1111/cbdd.13934
Amit Kumar ₁ , Bidhu Bhusan Karkara ₁ , Gautam Panda ₁

Affiliation

Tuberculosis (TB) is an infection caused by Mycobacterium tuberculosis (Mtb) and one of the deadliest infectious diseases in the world. Mtb has the ability to become dormant within the host and to develop resistance. Hence, new antitubercular agents are required to overcome problems in the treatment of multi-drug-resistant Tb (MDR-Tb) and extensively drug-resistant Tb (XDR-Tb) along with shortening the treatment time. Several efforts are being made to develop very effective new drugs for Tb, within the pharmaceutical industry, the academia and through publicâ€“private partnerships. This review will address the antitubercular activities, biological target, mode of action, synthetic approaches and thoughtful concept for the development of several new drugs currently in the clinical trial pipeline (up to October 2019) for tuberculosis. The aim of this review may be very useful in scheming new chemical entities (NCEs) for Mtb.

中文翻译：

用于结核病药物开发的临床开发管道中的新候选药物及其合成方法

结核病 (TB) 是由结核分枝杆菌引起的感染(Mtb) 和世界上最致命的传染病之一。Mtb 具有在宿主内休眠并产生抗药性的能力。因此，需要新的抗结核药物来克服耐多药结核病（MDR-Tb）和广泛耐药结核病（XDR-Tb）的治疗问题，同时缩短治疗时间。在制药行业、学术界和通过公私合作伙伴关系，正在努力开发非常有效的结核病新药。这篇综述将讨论目前处于临床试验管道（截至 2019 年 10 月）的几种新药的抗结核活性、生物学靶点、作用方式、合成方法和深思熟虑的概念。

更新日期：2021-08-15

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11